By Mike LaSusa ( April 9, 2020, 11:32 PM EDT) -- Gilead Sciences Inc. urged the Federal Circuit on Thursday to nix a Merck & Co. subsidiary's bid for the full court to review a panel decision that wiped out a $2.5 billion verdict in a patent dispute, calling the Merck unit's "attacks" on the panel's ruling "an exercise in selective omission."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.